Movetis
Movetis was acquired by Shire in 2010 for €428 million. Movetis focused on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. It was created by a team of entrepreneurs led by Dirk Reyn as a spin-off from Johnson & Johnson. Its products address GI disorders, such as severe chronic constipation, ascites, pediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-esophageal reflux disease. Movetis brought to market Resolor, a drug for chronic constipation.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Exit
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.